SEC Form 4
Helus Pharma Inc. (HELP) insider trading
In the 12 months to Oct 26, 2026, 4 HELP insiders reported open-market purchases of $9.7M across 9 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $9.7M
- 9 filings
Who traded HELP, and when
- Purchase
HELP daily close from Jan 5, 2026 to Oct 26, 2026, between $3.87 and $14.02, last $10.61. 0 sale and 9 purchase filings by 4 insiders, marked at their filing dates. Paul Glavine, Chief Growth Officer: bought $4.7M across 4 filings, first filed Sep 9, 2026, last Sep 11, 2026. Eric H. L. So, Executive Chair: bought $3.6M across 3 filings, first filed Sep 9, 2026, last Sep 11, 2026. Michael Halstead, Chief Executive Officer: bought $1.3M across 1 filing, first filed Sep 21, 2026, last Sep 21, 2026. Greg Cavers, Chief Financial Officer: bought $38.7K across 1 filing, first filed Oct 1, 2026, last Oct 1, 2026.
Largest mark · tap a row for others
Paul Glavine · Chief Growth Officer
Filing 1 of 4 within a week · $4,715,337 total
Purchase $1,042,677
90,000 shares at $11.59 avg
Filed Sep 9, 2026 · traded Aug 31
Close on filing date $13.68
Paul Glavine · Chief Growth Officer
Chief Growth Officer
$4.7M boughtEric H. L. So · Executive Chair
Executive Chair
$3.6M boughtMichael Halstead · Chief Executive Officer
Chief Executive Officer
$1.3M boughtGreg Cavers · Chief Financial Officer
Chief Financial Officer
$38.7K boughtOpen-market trades
9 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Paul Glavine | Chief Growth Officer | — | $4.7M | 4 | — | |
| Eric H. L. So | Executive Chair | — | $3.6M | 3 | — | |
| Michael Halstead | Chief Executive Officer | — | $1.3M | 1 | — | |
| Greg Cavers | Chief Financial Officer | — | $38.7K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Greg Cavers Chief Financial Officer | Purchase | 3,000 | $12.91 | $38.7K | 3,000 | |
traded | Michael Halstead Chief Executive Officer | Purchase | 100,000 | $13.47 | $1.3M | 168,568 | |
traded | Eric H. L. So Executive Chair | Purchase | 100,000 | $12.39 | $1.2M | 4,465,014 | |
traded | Paul Glavine Chief Growth Officer | Purchase | 100,000 | $12.47 | $1.2M | 4,271,252 | |
traded | Paul Glavine Chief Growth Officer | Purchase | 100,000 | $12.47 | $1.2M | 4,271,252 | |
traded | Paul Glavine Chief Growth Officer | Purchase | 100,000 | $11.78 | $1.2M | 4,171,252 | |
traded | Eric H. L. So Executive Chair | Purchase | 100,000 | $12.09 | $1.2M | 4,365,014 | |
traded | Paul Glavine Chief Growth Officer | Purchase | 90,000 | $11.59 | $1.0M | 4,071,252 | |
traded | Eric H. L. So Executive Chair | Purchase | 95,000 | $11.81 | $1.1M | 4,265,014 |
GET /stocks/filings/vX/form-4?tickers=HELP&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"HELP"
],
"issuer_cik": "0001833141",
"owner_cik": "0002116548",
"accession_number": "0000912282-26-001334",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-29",
"issuer_name": "Helus Pharma Inc.",
"issuer_trading_symbol": "HELP",
"owner_name": "Cavers Greg",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-29",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 3000,
"transaction_price_per_share": 12.91,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3000,
"transaction_value": 38730,
"direct_or_indirect": "I",
"nature_of_ownership": "Held by spouse",
"footnotes": [
{
"id": "F1",
"description": "Converted from Canadian purchase price of C$18.3157 using an exchange rate of C$1.4188 = US$1.00."
}
]
},
{
"tickers": [
"HELP"
],
"issuer_cik": "0001833141",
"owner_cik": "0001521548",
"accession_number": "0000912282-26-001293",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-21",
"issuer_name": "CYBIN INC.",
"issuer_trading_symbol": "CYBN",
"owner_name": "Halstead Michael",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-21",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 100000,
"transaction_price_per_share": 13.4705,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 168568,
"transaction_value": 1347050,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.395 to $13.53, inclusive. The reporting person undertakes to provide to Cybin Inc., any security holder of Cybin Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 2 records
- Grants and awards2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Helus Pharma Inc.'s CEO sold stock?
No. Michael Halstead (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is HELP’s insider data?
These are HELP Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track HELP insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for HELP every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.